MUNICH (Germany), 10th June, 2021 – leon-nanodrugs GmbH (‘LEON’), the Munich based nanotechnology company, has announced today the appointment of Dr Paul Jenkins as Chief Business Officer. Paul is uniquely positioned to support LEON’s strategic goals in building a business focused on providing nucleic acids, biologics and other drugs by using LEON’s proprietary continuously-manufactured nanoparticle technology. Paul brings over 25 years of experience in business development and senior management roles within the pharmaceutical and health care industries and will lead the business activities for the company. He has assumed his new role in April 2021.

Paul Jenkins is a pro-active Business Development (BD) professional with considerable international experience and has managed BD and sales teams in the US, EU, UK and Japan. He has amassed a wealth of deal-making and alliance management experience including multiple deals across a variety of therapeutic areas as proteins, peptides and biologicals. Paul has served on several Boards of start-ups. Previous roles include Chief Commercial Officer at Sisaf, Head of Business Development at Impel NeuroPharma, Vice President Business Development at Catalent, CEO at Adjuvantix and Vice President Business Development at West Pharmaceutical Services.

Paul is an immunologist by training and has a strong commercial track record in Drug Product (DP), Drug Delivery including nanoparticle and proprietary technologies, Pre-Clinical Development and Manufacturing as well as a strong knowledge of the healthcare market.

Andrea Cusack LEON’s CEO said “Paul is a result-driven team player with a proven ability to find solutions and build strong lasting relationships and alliances. We are delighted to welcome him to the LEON team.”

Paul commented “It is a pleasure to assist Andrea, whom I have worked with for over 20 years, and the rest of the LEON team in continuing to build a great business that has particular current resonance given its game-changing ability in nanoparticle manufacturing and commercialisation.”